Clinical Evidence And Indication ExpansionPublished data indicating ProSense activity in non-small cell lung cancer supports potential indication expansion beyond breast cancer, creating prospects for new market opportunities.
Commercial Adoption And ReimbursementIdentification of multiple reimbursable post-market study sites alongside improving preliminary U.S. sales suggests increasing commercial traction and broader clinician uptake.
Regulatory ApprovalFDA marketing authorization for ProSense is expected to expand U.S. demand and attract international interest, supporting revenue growth as commercialization advances.